Article
The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
British journal of haematology - 1 Nov 2005
Tefferi Ayalew, Lasho Terra L, Schwager Susan M, Steensma David P, Mesa Ruben A, Li Chin-Yang, Wadleigh Martha, Gary Gilliland D
Abstract excerpt
An association between an activating JAK2 mutation (JAK2(V617F)) and BCR/ABL-negative myeloproliferative disorders was recently reported in multiple simultaneous publications. In the current study, mutation analysis for JAK2(V617F) was performed in peripheral blood mononuclear cells (PBMC) from 157 patients with myelofibrosis with myeloid metaplasia (MMM) including 117 with agnogenic (AMM), 22 with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.